BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

Rhea-AI Summary

BridgeBio (Nasdaq: BBIO) announced two investor events next week: a webinar to share topline Phase 3 interim results from the LGMD2I/R9 FORTIFY study on Monday, October 27, 2025 at 8:00 AM ET, and its Q3 2025 earnings call on Wednesday, October 29, 2025 at 4:30 PM ET. Management will host both business update calls and provide webcasts accessible via the company’s Investors > Events and Presentations page.

A replay of each webcast will be available on the BridgeBio investor website for 90 days following the events.

PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate business update calls to share the following:

• Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) FORTIFY Phase 3 Interim Analysis Topline Results Webinar: Monday, October 27 at 8:00 am ET
  
• Q3 2025 Earnings: Wednesday, October 29 at 4:30 pm ET

To access the live webcast for BridgeBio's calls, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

When will BridgeBio (BBIO) present FORTIFY Phase 3 interim topline results?

BridgeBio will present LGMD2I/R9 FORTIFY Phase 3 interim topline results on Monday, October 27, 2025 at 8:00 AM ET.

When is BridgeBio's (BBIO) Q3 2025 earnings call scheduled?

BridgeBio's Q3 2025 earnings call is scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

How can investors access BridgeBio (BBIO) webcasts for the FORTIFY results and Q3 2025 earnings?

Investors can access live webcasts via the company’s Investors > Events and Presentations page at https://investor.bridgebio.com.

Will the BridgeBio (BBIO) webcasts be available after the live events?

Yes. Replays of the webcasts will be available on the BridgeBio investor website for 90 days after each event.

What topics will BridgeBio (BBIO) management cover during the October 27 and October 29 calls?

Management will present the FORTIFY Phase 3 interim topline results on October 27 and discuss Q3 2025 financial results on October 29.

Is the October 27 FORTIFY presentation the final Phase 3 readout for BBIO's BBP-418?

The October 27 event is described as a presentation of interim topline results; it does not state whether this is a final readout.